| Literature DB >> 26530743 |
Gregory M M Videtic1, Chen Hu2, Anurag K Singh3, Joe Y Chang4, William Parker5, Kenneth R Olivier6, Steven E Schild7, Ritsuko Komaki4, James J Urbanic8, Robert D Timmerman, Hak Choy9.
Abstract
PURPOSE: To compare 2 stereotactic body radiation therapy (SBRT) schedules for medically inoperable early-stage lung cancer to determine which produces the lowest rate of grade ≥3 protocol-specified adverse events (psAEs) at 1 year. METHODS AND MATERIALS: Patients with biopsy-proven peripheral (≥2 cm from the central bronchial tree) T1 or T2, N0 (clinically node negative by positron emission tomography), M0 tumors were eligible. Patients were randomized to receive either 34 Gy in 1 fraction (arm 1) or 48 Gy in 4 consecutive daily fractions (arm 2). Rigorous central accreditation and quality assurance confirmed treatment per protocol guidelines. This study was designed to detect a psAEs rate >17% at a 10% significance level (1-sided) and 90% power. Secondary endpoints included rates of primary tumor control (PC), overall survival (OS), and disease-free survival (DFS) at 1 year. Designating the better of the 2 regimens was based on prespecified rules of psAEs and PC for each arm.Entities:
Mesh:
Year: 2015 PMID: 26530743 PMCID: PMC4744654 DOI: 10.1016/j.ijrobp.2015.07.2260
Source DB: PubMed Journal: Int J Radiat Oncol Biol Phys ISSN: 0360-3016 Impact factor: 7.038